2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry index, is up by nearly 13% year to date.
Still, it's too early to say whether the industry will keep up this momentum all year long; we are only in March. But no matter what happens to this sector, let's consider two biotech stocks worth buying and holding on to for a while: Regeneron Pharmaceuticals (NASDAQ: REGN) and Exelixis (NASDAQ: EXEL).
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
850,00 €
1,82 %
Regeneron Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Ein positives Kurspotenzial für Regeneron Pharmaceuticals Inc. ist gegeben, mit einem Kursziel von 957 € über dem aktuellen Kurs von 850.0 €.
